News >

Future of AYA ALL Research Should Include Eliminating MRD, Treating High-Risk Patients

Jason Harris
Published: Thursday, Sep 13, 2018

Wendy Stock, MD,
Wendy Stock, MD
Following survival improvements in the field of adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), researchers must turn their focus to lowering toxicity, delivering treatment to high-risk subgroups, eliminating minimal residual disease (MRD) early in treatment, and addressing the unique psychosocial and economic challenges facing this often-overlooked patient population, according to Wendy Stock, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication